| 0 (0%) | 10-14 18:22 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.09  |
1-year : | 4.78 |
| Resists | First : | 3.5 |
Second : | 4.09 |
| Pivot price | 3.2 |
|||
| Supports | First : | 2.51 |
Second : | 1.89 |
| MAs | MA(5) : | 3.4 |
MA(20) : | 2.91 |
| MA(100) : | 2.4 |
MA(250) : | 1.52 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 93 |
D(3) : | 93.7 |
| RSI | RSI(14): 74.8 |
|||
| 52-week | High : | 3.5 | Low : | 0.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CTMX ] has closed below upper band by 30.5%. Bollinger Bands are 29.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.51 - 3.53 | 3.53 - 3.54 |
| Low: | 3.18 - 3.19 | 3.19 - 3.2 |
| Close: | 3.4 - 3.42 | 3.42 - 3.44 |
Tue, 14 Oct 2025
News impact scoring models applied to CTMX - July 2025 Analyst Calls & Real-Time Stock Price Movement Reports - newser.com
Tue, 14 Oct 2025
Oppenheimer Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Tue, 14 Oct 2025
CytomX Therapeutics (CTMX) Gains Momentum with Positive CX-2051 Data - GuruFocus
Mon, 13 Oct 2025
CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible - Seeking Alpha
Sat, 11 Oct 2025
CytomX Therapeutics (NASDAQ:CTMX) Shares Down 7% - Should You Sell? - MarketBeat
Thu, 14 Aug 2025
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 165 (M) |
| Shares Float | 120 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 90 (%) |
| Shares Short | 31,370 (K) |
| Shares Short P.Month | 26,970 (K) |
| EPS | 0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | 34 % |
| Operating Margin | -6.9 % |
| Return on Assets (ttm) | 16.1 % |
| Return on Equity (ttm) | 108.2 % |
| Qtrly Rev. Growth | -25.8 % |
| Gross Profit (p.s.) | 0.85 |
| Sales Per Share | 0.85 |
| EBITDA (p.s.) | 0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | 6.84 |
| PEG Ratio | 0 |
| Price to Book value | 4.68 |
| Price to Sales | 3.99 |
| Price to Cash Flow | -7.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|